Mark Entwistle
Presidente presso Chibas Consulting, Inc.
Posizioni attive di Mark Entwistle
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Chibas Consulting, Inc. | Direttore/Membro del Consiglio | 18/01/2011 | - |
| Presidente | 14/01/2011 | - |
Storia della carriera di Mark Entwistle
Precedenti posizioni note di Mark Entwistle
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Direttore/Membro del Consiglio | 09/10/1997 | - |
Statistiche
Distribuzione geografica
| Regno Unito | 2 |
| Canada | 2 |
Posizioni
| Director/Board Member | 2 |
| President | 1 |
Settori
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
| Chibas Consulting, Inc. |
- Borsa valori
- Insiders
- Mark Entwistle
- Esperienza
